Generic Name:
Nivolumab in combination with Ipilimumab
Project Status:
Complete
Therapeutic Area:
NSCLC
Manufacturer:
Bristol-Myers Squibb
Brand Name:
Opdivo in combination with Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0218-000
NOC Date:
Details
Strength:
10 mg/mL
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (NSCLC)
Funding Request:
Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations
Review Status:
Notification to Implement Issued
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued: